The First Steps in the New Era of FSHD Trials

Trial Readiness, Execution and Evaluation

Joost Kools • Boek • paperback

• Samenvatting
  Free download at https://doi.org/10.54195/9789465150215
  
  Facioscapulohumeral dystrophy is a chronic, hereditary muscle disease that causes slow decline in muscle strength. Ultimately, approximately 20% of patients become wheelchair dependent. Due to the wide variation in disease pattern, we have seen that the more generic questionnaires and clinical tests (such as muscle strength) are not ideal as outcome measures for drug trials in FSHD. We also tested a drug called losmapimod for safety and effectiveness. This study showed that it was safe and may have shown an inhibitory effect on the disease. A later study showed that the drug was ineffective (not in this thesis). Muscle biopsies are often performed in FSHD drug studies. Our research shows that these muscle biopsies cause a lot of (short-term) pain. It therefore remains important to look for new methods and outcome measures. Finally, we concluded through interviews that participation in the drug study was experienced as positive.
• Productinformatie
  Binding : Paperback
  Distributievorm : Boek (print, druk)
  Formaat : 170mm x 240mm
  Aantal pagina's : 226
  Uitgeverij : Radboud University Press
  ISBN : 9789465150215
  Datum publicatie : 03-2025
  
• Inhoudsopgave
  niet beschikbaar
• Reviews (0 uit 0 reviews)
  Wil je meer weten over hoe reviews worden verzameld? Lees onze uitleg hier.